Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma.
- Author:
Sumi YUN
1
;
Ping Li SUN
;
Yan JIN
;
Hyojin KIM
;
Eunhyang PARK
;
Soo Young PARK
;
Kyuho LEE
;
Kyoungyul LEE
;
Jin Haeng CHUNG
Author Information
- Publication Type:Original Article
- Keywords: Aquaporin 1; Adenocarcinoma; Tissue array analysis; Invasion; Epithelial-mesenchymal transition
- MeSH: Adenocarcinoma*; Aquaporin 1*; Cadherins; Disease-Free Survival; Epithelial-Mesenchymal Transition; Humans; Immunohistochemistry; Lung*; Lymphoma; Multivariate Analysis; Neoplasm Metastasis; Phosphotransferases; Prognosis*; Recurrence; Seoul; Tissue Array Analysis; Vimentin
- From:Journal of Pathology and Translational Medicine 2016;50(4):251-257
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Aquaporin 1 (AQP1) overexpression has been shown to be associated with uncontrolled cell replication, invasion, migration, and tumor metastasis. We aimed to evaluate AQP1 expression in lung adenocarcinomas and to examine its association with clinicopathological features and prognostic significance. We also investigated the association between AQP1 overexpression and epithelial-mesenchymal transition (EMT) markers. METHODS: We examined AQP1 expression in 505 cases of surgically resected lung adenocarcinomas acquired at the Seoul National University Bundang Hospital from 2003 to 2012. Expression of AQP1 and EMT-related markers, including Ecadherin and vimentin, were analyzed by immunohistochemistry and tissue microarray. RESULTS: AQP1 overexpression was associated with several aggressive pathological parameters, including venous invasion, lymphatic invasion, and tumor recurrence. AQP1 overexpression tended to be associated with higher histological grade, advanced pathological stage, and anaplastic lymphoma kinase (ALK) translocation; however, these differences were not statistically significant. In addition, AQP1 overexpression positively correlated with loss of E-cadherin expression and acquired expression of vimentin. Lung adenocarcinoma patients with AQP1 overexpression showed shorter progression-free survival (PFS, 46.1 months vs. 56.2 months) compared to patients without AQP1 overexpression. Multivariate analysis confirmed that AQP1 overexpression was significantly associated with shorter PFS (hazard ratio, 1.429; 95% confidence interval, 1.033 to 1.977; p=.031). CONCLUSIONS: AQP1 overexpression was thereby concluded to be an independent factor of poor prognosis associated with shorter PFS in lung adenocarcinoma. These results suggested that AQP1 overexpression might be considered as a prognostic biomarker of lung adenocarcinoma.
